trending Market Intelligence /marketintelligence/en/news-insights/trending/t8YzckDGyL589daxGRXYUg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Gilead acquires license to use 2 Xencor technologies for HIV treatments

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Gilead acquires license to use 2 Xencor technologies for HIV treatments

Gilead Sciences Inc. agreed to acquire a license to access Xencor Inc.'s Xtend and Cytotoxic XmAb technologies for developing and commercializing its experimental HIV infection treatment GS-9722.

Under the agreement, Gilead will have an exclusive license to use the technologies for GS-9722, or elipovimab, and up to three additional HIV treatments. Xencor retains the right to grant licenses for other antibodies directed to the target.

Xencor will receive an up-front payment and is eligible to receive milestone payments and royalties on developing and commercializing these products.

Financial details of the agreement were not disclosed.

Foster City, Calif.-based Gilead will be responsible for all development, regulatory and commercial activities. The biotech is evaluating GS-9722 in a phase 1 trial.

GS-9722 is a broadly neutralizing anti-HIV antibody that can potentially reduce or eliminate the number of HIV infected immune cells by killing them.

Xencor's Xtend technology helps increase binding capacity of the antibodies with certain cells lining the blood vessels, which protect antibodies from degradation. This helps improve antibody performance and results in longer drug exposure.

Cytotoxic XmAb technology improves immune system functions for eliminating tumors and other diseased cells.